GrantRegister

Federal Agency · National Institutes of Health

NIAMS P30 Centers Program (P30 - Clinical Trial Not Allowed)

Last updated: October 23, 2026

Posted October 9, 2026

Funding

Up to $500K

Closes

March 1, 2029

NAICS

541714

The overall goal of this program is to accelerate scientific discovery, improve research efficiency, and enhance the translation of research findings into improved health outcomes. Centers funded under this program will also foster multidisciplinary collaboration, support workforce development across career stages, and promote training in emerging areas such as data science, artificial intelligence, and implementation research. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS P30 Centers Program to support integrated research Centers within its mission areas of skin biology and diseases; bone, muscle, and orthopaedic research; and rheumatic diseases. The NIAMS P30 Centers Program supports Centers that provide coordinated research infrastructure, shared resources, and methodological expertise to advance basic, translational, and clinical research. These Centers are expected to integrate state-of-the-art research resources with capabilities that support clinical and translational research, including the development, testing, and dissemination of novel analytical methods, study designs, outcome measures, and data-driven approaches.

Eligibility

  • Funded by NIH

Award details

Award range: Up to $500K. Applications close on March 1, 2029 (860 days remaining).

Categories

Not categorized

Sign up at GrantRegister to see if this grant matches your organization.

Match my organization →

View application on Grants.gov →·Source: Grants.gov·Last seen Oct 23, 2026

Similar grants

GrantRegister provides information, not advice. Eligibility requirements and deadlines are set by the funder and can change without notice. Confirm eligibility, deadlines, and requirements with National Institutes of Health before applying.